Individual Members

  • Anne Osbourn

  • Michelle O’Malley

    Michelle A. O’Malley is an Associate Professor in the Department of Chemical Engineering at the University of California, Santa Barbara. She earned a B.S. in Chemical Engineering and Biomedical Engineering from Carnegie Mellon University in 2004 and a PhD in Chemical Engineering from the University of Delaware in 2009, where she worked with Prof. Anne Robinson to engineer overproduction of membrane proteins in yeast. O’Malley was a USDA-NIFA postdoctoral fellow in the Department of Biology at MIT and the Broad Institute, where she developed new strategies for cellulosic biofuel production. At UCSB, her research group develops synthetic biology tools to engineer protein synthesis within anaerobes and microbial consortia for sustainable chemical production, bioremediation, and natural product discovery. O’Malley’s research has been featured on NPR’s Science Friday, the BBC Newshour, the LA Times, and several other media outlets. She was named one of the 35 Top Innovators Under 35 in the world by MIT Technology Review in 2015, and is the recipient of the Presidential Early Career Award for Scientists and Engineers (PECASE), a DOE Early Career Award, an NSF CAREER award, the Camille Dreyfus Teacher-Scholar Award, the ACS BIOT Division Young Investigator Award, the ACS PMSE Division Young Investigator Award, an ACS WCC “Rising Star” Award, and a Hellman Faculty Fellowship.

  • Richard Murray

    Richard M. Murray received the B.S. degree in Electrical Engineering from California Institute of Technology in 1985 and the M.S. and Ph.D. degrees in Electrical Engineering and Computer Sciences from the University of California, Berkeley, in 1988 and 1991, respectively. He is currently the Thomas E. and Doris Everhart Professor of Control & Dynamical Systems and Bioengineering at Caltech. Murray’s research is in the application of feedback and control to networked systems, with applications in biology and autonomy. Current projects include analysis and design of biomolecular feedback circuits, synthesis of discrete decision-making protocols for reactive systems, and design of highly resilient architectures for autonomous systems.

  • Tae Seok Moon

    He has 24 years of research experience in chemistry, systems biology, and synthetic biology, including 5.5 years of industry experience (as of 2021). His research focus (2012-21; 15 grants; $7.3M external funding to him; $16M to the entire team) is understanding gene regulation, evolution, and metabolism, building sensors and genetic circuits, and engineering microbes to solve global problems, including climate crisis, waste valorization, plastic upcycling, sustainability, and health issues. He has published 52 papers, has filed 9 patents, and has given 51 invited and 118 contributed presentations. He has advised 26 PhD/Postdoctoral and 28 undergrad researchers. He is a Founder and Head of the SAB of Moonshot Bio. Several awards include a B&B Wang Award, an NSF CAREER award, an ONR YIP, a Sluder Fellowship (MIT), and the SNU President Prize. He is the Founding Chair of SynBYSS (Synthetic Biology Young Speaker Series) with more than 1000 global audiences.

    Twitter handle: @Moon_Synth_Bio

    LinkedIn Profile

  • June Medford

  • Timothy Lu

  • Chang Liu

    Professor Liu’s research is in the fields of synthetic biology, chemical biology, and directed evolution. He is particularly interested in engineering specialized genetic systems for rapid mutation and evolution in vivo to address problems ranging from protein engineering to developmental biology. For his group’s work, Professor Liu has been recognized with a number of awards including the NIH Transformative Research Award, the NIH New Innovator Award, the Moore Inventor Fellowship, the Sloan Research Fellowship, the Beckman Young Investigator Award, the Dupont Young Professor Award, and the ACS Synthetic Biology Young Innovator Award.

  • Wendell Lim

  • Jan Leach

    Jan Leach

  • Tanja Kortemme

  • Ahmad Khalil

    Ahmad (Mo) Khalil is Associate Professor of Biomedical Engineering and the Founding Associate Director of the Biological Design Center at Boston University. He is also a Visiting Scholar at the Wyss Institute for Biologically Inspired Engineering at Harvard University. His research is interested in how molecular circuits enable core cellular functions, such as decision-making, computation, and epigenetic memory. His team applies synthetic biology approaches to interrogate the function and evolution of these cellular systems. He is recipient of numerous awards, including the Presidential Early Career Award for Scientists and Engineers (PECASE), NIH New Innovator Award, NSF CAREER Award, DARPA Young Faculty Award, and the Hartwell Foundation Biomedical Research Award, and he has received numerous awards for teaching excellence at both the Department and College levels. Mo was an HHMI Postdoctoral Fellow with Dr. James Collins at Boston University. He obtained his Ph.D. from MIT and his B.S. (Phi Beta Kappa) from Stanford University

  • Richard Kitney

    Richard Kitney

    Kitney is Professor of Biomedical Systems Engineering at Imperial College London and Co-Director of the UK’s National Industrial Translation Centre for Synthetic Biology/Engineering Biology (SynbiCITE). Kitney is a Fellow of The Royal Academy of Engineering (the UK’s National Academy of Engineering) and Chaired the Academy’s Inquiry into Synthetic Biology. He a member of the UK’s Ministerial Leadership Council for Engineering Biology. Kitney (with Professor Paul Freemont) has been responsible for founding and developing the Imperial College Engineering/Biology Hub. Kitney has considerable business experience, particularly in relation to start-ups and SMEs. For example, he was Co-founder and Chairman of Visbion Ltd (until December 2022) – a medical imaging and biomedical information systems company, with over 1000 installations in 10 countries. In 2022 Kitney Co-founded SynBioVen (SBV), a venture fund focussing on investment in UK Start-ups and SMEs in engineering biology. He is a Director of SBV. Kitney has published over 300 papers in the fields of engineering biology, mathematical modelling, biomedical information systems, and medical imaging and has worked extensively in and with industry. He was an author of both the UK Government’s Roadmaps for Synthetic Biology. Kitney is an Academician of the International Academy of Biomedical Engineering and is also a Fellow of AIMBE (the America Academy of Biomedical Engineering). In 2006 he was made an Honorary Fellow of both The Royal College of Physicians and The Royal College of Surgeons. In 2016 he was made a Fellow of The Royal Society of Edinburgh.

    In June 2001, Kitney was awarded The Order of the British Empire (OBE) in the Queen’s Birthday Honours List for services to Information Technology in Healthcare.

  • Jay Keasling

  • Terry Johnson

  • Michael Jewett

    Michael Jewett is a Professor of Bioengineering at Stanford University. He received his B.S. from UCLA and PhD from Stanford University, both in Chemical Engineering. He completed postdoctoral studies at the Center for Microbial Biotechnology in Denmark and the Harvard Medical School. Jewett was also a guest professor at the Swiss Federal Institute of Technology (ETH Zurich). His research group focuses on advancing synthetic biology research to support planet and societal health, with applications in medicine, manufacturing, sustainability, and education.

  • Nathan Hillson

    Nathan Hillson

    Dr. Hillson earned his Ph.D. in Biophysics from Harvard Medical School. He did his postdoctoral work in Developmental (Micro)Biology at Stanford University School of Medicine. Dr. Hillson's work has spanned the realms of the private (notably as co-founder/Chief Scientific Officer at TeselaGen) and public biotechnology sectors. As Department Head of BioDesign within the Biological Systems & Engineering Division, Dr. Hillson leads scientists and engineers within Lawrence Berkeley National Laboratory whose domain expertise spans synthetic biology, metabolic engineering, microbiology, microbial communities, software engineering, and laboratory automation engineering. As overall Principal Investigator of the U.S. DOE Agile Biofoundry, Dr. Hillson leads scientists/engineers across 8 U.S. DOE National Labs towards the development of a public infrastructure that enables the private sector to reduce the cost and accelerate bioprocess commercialization timelines. This infrastructure complements discovery engines (such as the Joint Genome Institute, to which Dr. Hillson also contributes).

  • Karmella Haynes

    Karmella Haynes

  • John Glass

    John Glass

    Dr. John Glass is a Professor and leader of the J. Craig Venter Institute (JCVI) Synthetic Biology and Bioenergy Group. His expertise is in molecular biology, microbial pathogenesis, RNA virology, and microbial genomics. Glass is part of the Venter Institute team that created the first bacterial cell with a chemically synthesized genome and a bacterial cell with a synthetic genome encoding only the essential gene set needed for life. In reaching this milestone the Venter Institute scientists developed the fundamental techniques of the new field of synthetic genomics including genome transplantation and genome assembly. Glass was also leader of the JCVI project that rapidly made synthetic influenza virus vaccine strains in collaboration with Novartis Vaccines and Diagnostics, Inc. and Synthetic Genomics, Inc. At the JCVI he has also led the bacterial outer membrane vesicle based vaccine, genome transplantation, and Mycoplasma genitalium minimal genome projects, and projects studying other mycoplasma and ureaplasma species. Glass and his Venter Institute colleagues are now using synthetic biology and synthetic genomics approaches developed at the JCVI to create cells and organelles with redesigned genomes to make microbes that can produce biofuels, pharmaceuticals, and industrially valuable molecules. Glass is an adjunct faculty member of the University of Maryland at College Park Cellular and Molecular Biology Program, one of the founding members of the Build-A-Cell program to create synthetic cells, and member of the Global Viral Network Scientific Leadership Board.

    Prior to joining the JCVI, Glass spent five years in the Infectious Diseases Research Division of the pharmaceutical company Eli Lilly. There he was a member of the hepatitis C virology group and a microbial genomics group (1998-2003). There Glass was part of the Lilly and Vertex Pharmaceuticals Inc. team that developed Incivek, one of the first drugs to cure hepatitis C virus.
    Glass earned his undergraduate (Biology) and graduate degrees (Genetics) from the University of North Carolina at Chapel Hill. His Ph.D. work was on RNA virus genetics in the laboratory of Gail Wertz. He was on the faculty and did postdoctoral fellowships in the Microbiology Department of the University of Alabama at Birmingham in polio virology with Casey Morrow and mycoplasma pathogenesis with Gail Cassell (1990-1998). On sabbatical leave in Ellson Chen’s lab at Applied Biosystems, Inc. (1995-1997) he sequenced the genome of Ureaplasma parvum and began his study of bacterial genomics.

  • Emma Frow

    Emma’s research and teaching activities focus on the governance of emerging biotechnologies, especially synthetic biology and biological engineering. She started her research life as a bioscientist, completing a PhD in biochemistry at the University of Cambridge, and then re-trained in the field of science & technology studies (STS) at the University of Edinburgh and Harvard’s Kennedy School of Government. Her current faculty position at Arizona State University is a joint appointment between the School for the Future of Innovation in Society and the School of Biological & Health Systems Engineering, which allows her to straddle the worlds of science policy and bioengineering. Emma has been studying the field of synthetic biology for a decade now, working on a variety of social scientific and interdisciplinary projects in Europe and the US. She has specific research interests in the relationship between engineering and biology, and in the standards and infrastructures (physical, digital, social) being designed to support the development of this field. She sees standards and infrastructures as tools of governance, and is interested in identifying the values, design choices and visions of the future that get built into new infrastructures for biotechnology.

    • Back to top ⇑